“…Similarly, metabolic diseases such as diabetes mellitus are known to affect chemotaxis, phagocytosis, activation, and antigen presentation by phagocytes in response to MTB, and this defect does not improve with insulin (Moutschen et al, 1992). Importantly, IFN- production was found to be impared in hyperglycemia (Yamashiro et al, 2005), but another study showed that both IGRA results were not affected in diabetes mellitus patients (Walsh et al, 2011). Intermediate results have been found to be also associated with lower serum albumin and double immunomodulatory therapy (Papay et al,2011).…”